University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Department of Emergency Medicine, University of Alabama, Birmingham, AL, United States.
Resuscitation. 2017 Dec;121:98-103. doi: 10.1016/j.resuscitation.2017.10.007. Epub 2017 Oct 12.
Cessation of blood flow during out-of-hospital cardiac arrest (OHCA) results in microvascular thrombosis, protracted hypoperfusion after return of spontaneous circulation and damage to vital organs. We tested the hypothesis that pre-arrest antiplatelet and anticoagulant medication use would be associated with less post-arrest organ dysfunction and better outcomes.
We included OHCA patients treated from January 2005 to October 2014 at a single academic medical center. We combined our prospective OHCA registry of clinical and demographic data with a structured chart review to abstract home antiplatelet and anticoagulant medications. We fit unadjusted and adjusted regression models to test the association of antiplatelet and anticoagulant medication use with early post-arrest illness severity, survival and functionally favorable recovery.
Of 1054 subjects, 295 (28%) were prescribed an antiplatelet agent and 147 (14%) were prescribed an anticoagulant prior to arrest. In adjusted models, antiplatelet agents were associated with lower post-arrest illness severity (adjusted OR 0.50 95% CI 0.33-0.77), greater odds of survival to discharge (adjusted OR 1.74 95% CI 1.08-2.80) and greater odds favorable functional outcome (adjusted OR 2.11 95% CI 1.17-3.79). By contrast, anticoagulation via any agent was not associated with illness severity, survival to discharge or favorable outcome.
Preventing intra-arrest and post-arrest microvascular thrombosis via antiplatelet agents could represent a novel therapeutic target to improve outcomes after OHCA.
院外心脏骤停 (OHCA) 期间血流停止会导致微血管血栓形成,自主循环恢复后灌注持续时间延长,重要器官受损。我们假设在心脏骤停前使用抗血小板和抗凝药物与心脏骤停后器官功能障碍程度降低和更好的预后相关。
我们纳入了 2005 年 1 月至 2014 年 10 月在一家学术医疗中心接受治疗的 OHCA 患者。我们将前瞻性 OHCA 临床和人口统计学数据登记与结构化图表审查相结合,以提取家庭使用的抗血小板和抗凝药物。我们拟合了未调整和调整后的回归模型,以检验抗血小板和抗凝药物的使用与心脏骤停后早期疾病严重程度、生存和功能良好的恢复之间的关联。
在 1054 名患者中,295 名(28%)在心脏骤停前服用了抗血小板药物,147 名(14%)在心脏骤停前服用了抗凝药物。在调整后的模型中,抗血小板药物与心脏骤停后疾病严重程度降低相关(调整后的 OR 0.50,95% CI 0.33-0.77)、存活至出院的几率更高(调整后的 OR 1.74,95% CI 1.08-2.80)和获得更好的功能结果的几率更高(调整后的 OR 2.11,95% CI 1.17-3.79)。相比之下,任何药物的抗凝治疗与疾病严重程度、存活至出院或良好预后均无相关性。
通过抗血小板药物预防心脏骤停期间和心脏骤停后的微血管血栓形成可能代表改善 OHCA 后预后的新治疗靶点。